Drug combinations are becoming a standard treatment of many complex diseases due to their 14 capability to overcome resistance to monotherapy. Currently, in the preclinical drug combination 15 screening, the top hits for further study are often selected based on synergy alone, without considering 16 the combination efficacy and toxicity effects, even though these are critical determinants for the 17 clinical success of a therapy. To promote the prioritization of drug combinations based on integrated 18 analysis of synergy, efficacy and toxicity profiles, we implemented a web-based open-source tool, 19
Introduction 26
High throughput screening (HTS) of approved and investigational agents in preclinical model systems 27 has been established as an efficient technique to identify candidate drug combinations to be further 28 developed as safe and effective treatment options for many diseases, such as HIV, tuberculosis and 29 various types of cancers [1, 2] . Currently, the selection of top combinations for further development drug combinations based on integrated efficacy, synergy and toxicity profiles ( Fig.1) . Therefore, for 48 each drug combination, SynToxProfiler first calculates a normalized volume under dose-response 49 surface to quantify combination efficacy based on dose-response measurements on diseased cells, e.g. 50 patient derived primary cells (see Suppl. Fig. 1 ). Then, the combination synergy between each drug 51 pair is estimated using one of the synergy scoring models: Highest Single-Agent [5], Bliss 52 independence [6], Loewe additivity [7], or Zero Interaction Potency [8] , as implemented in the 53 SynergyFinder R-package [9] . Normalized volume under the dose-synergy surface is utilized to 54 quantify final combination synergy score (Suppl. Fig. 1A ). Next, using the measurements on control 55 cells, if available, the normalized volume under dose-response matrix is calculated to estimate 56 combination toxicity (Suppl. Fig. 1 ). Finally, SynToxProfiler ranks the drug combinations based on 57 integrated combination synergy, efficacy and toxicity (STE) score. Alternatively, if measurement on 58 control cells are not available, then the ranking of drug pairs can also be done based merely on 59 combination synergy and efficacy. As a result of the interactive analysis, SynToxProfiler provides a 60 web-based exportable report, which allows users to interactively explore their results ( Fig. 1 and  61 Suppl. Fig 2) . An interactive example of web-based report is given at 62 https://syntoxprofiler.fimm.fi/example. A more detailed description of the calculations and workflow is 63 provided in the technical documentation, https://syntoxprofiler.fimm.fi/howto. The normalized volume under the dose-response surface is calculated while quantifying combination 76 efficacy and toxicity based on measurements on diseased and control cells, respectively (Suppl. Fig. 1 ). 77
Synergy score was calculated based on measurements on diseased cells as normalized volume under 78 synergy matrix (excess matrix of combination responses over expected responses determined by one of 79 the synergy models, such as Bliss). For each combination AB of drugs, A and B, the normalized 80 volume under the dose-response surface V AB is calculated as: 81 approach for volume-based scoring normalizes for the different dose-ranges measured in different drug 86 combinations, as commonly occurring in HTS settings. The extension of formulation for volume -87 based scoring of synergy, efficacy and toxicity profiles for multi-drug combinations (3 or more drugs) 88 is given in the supplementary file. 89 90
Ranking of drug combinations 91
SynToxProfiler ranks the drug combinations based on an integrative analysis of synergy, toxicity and 92 efficacy, quantified as STE score. First, the difference in efficacy (E AB ) and toxicity volume scores 93 (T AB ) is calculated for each drug combination to quantify a selective response in diseased cells, relative 94 to that of control cells. We defined this difference as a selective efficacy score (sE AB ) of a drug 95 combination. This theoretical concept for selective efficacy has been adopted from the single drug 96 dose-response assays, where the difference in normalized areas under the curve (AUC) between 97 diseased and healthy cells is often used to calculate the patient-specific drug efficacies [10, 11]. The 98
final STE score is given by averaging two different ranks of (i) combination synergy score (S AB) (the 99 higher is the synergy, the higher is the rank), and (ii) selective combination efficacy (sE AB ) (the higher 100 is selective efficacy, the higher is the rank): 101
where S AB and sE AB are the synergy and selective efficacy scores, respectively, for a combination of 102 drug A and B, calculated using the normalized volume under the dose-response surface; and N is the 103 total number of drug combinations being tested. However, since calculation of STE score using the 104 whole dose-response matrix may miss some of the top hit drug combinations with a narrow synergistic 105 dose window, SynToxProfiler also offers the users a possibility to rank combinations based on the 106 selective efficacy and synergy scores calculated only at the most synergistic area of the drug 107 combination matrix (defined as the 3x3 concentration window with the highest synergy in the dose-108 response matrix), instead of the default full matrix calculation. 109 110
Data submission and reporting 111
The default input of SynToxProfiler is a text or xlsx file that comprises annotations of each drug 112 combination dose-response matrix, including drug names, concentrations, cell types (e.g. sample or 113 control), and phenotypic responses (e.g. relative inhibition). The number of drug combinations 114 provided in the input file is unrestricted. More information on the input file format is given in the 115 website documentation (https://syntoxprofiler.fimm.fi/howto/). As the result, SynToxProfiler provides 5 plots. Publication-quality figures (e.g. heatmap for dose-response and synergy matrix, 2D and 3D 118 scatter plot for different scores) can be exported in PDF files, as well as all the calculated scores can be 119 downloaded in an xlsx file. 120
Hematological Registry and biobank (FHRB). The written informed consents were obtained from both 126 participants and the study was carried in accordance with the principles of Helsinki declarations. 127 Twenty combinations of drugs with different mechanisms of actions (see Supplementary Table S1 ) 128
were tested on the PBMCs in 8x8 dose-response matrix assay as described previously [12, 13] we used a published dataset of 77 drug combinations tested as anti-viral agents where the drug 170 combinations' efficacy and toxicity were tested in Ebola-infected and non-virus-infected Huh7 liver 171 cells, respectively. SynToxProfiler ranked established combinations (e.g. clomifene-sertraline and 172 sertraline-toremifene) that inhibit EBOV fusion to cell surface as top hits for further study (Additional 173
File 2). All the three drugs (clomifene, sertraline and toremifene) showed survival benefit in in-vivo We compared the synergy and selective efficacy level of the top hits prioritized based on the STE 180 score, synergy score and selective efficacy scores, using the 77 combinations in the Ebola dataset. The 181 top combinations identified by STE scores had a notably higher selective efficacy as well as higher 182 synergy (shown by arrow in Fig. 2A) , indicating that STE score represents a proper balance between 183 high selective efficacy and synergy. Additionally, we observed a marked overlap (65%) between the 184 top-10% of analyzed combinations prioritized based on STE score and synergy score, as well as based 185 on the STE score and selective efficacy score (50% overlap), as shown in Fig. 2B . In contrast, there 186 was a smaller overlap (41%) between the top-10% hits selected based on selective efficacy and 187 synergy scores. Further, a low Pearson correlation (r=0.22) between selective efficacy and synergy was 188 observed. These results indicate that synergy and selective efficacy are independent drug combination 189 components, which cannot be used alone to prioritize potent and less toxic synergistic drug SyntoxProfiler ranked clomiphene citrate and sertraline HCl combination (STE=0.96) as the top hit 204 ( Fig.3) , despite its lower synergy as compared to more synergistic toremifene citrate and apilimod pair 205 (STE=0.86). This is due to a higher toxicity (13.30 vs 24.60) of latter, although both of the drug 206 combinations have similar efficacy scores (70.88 vs 68.20). The lower ranking of combinations 207 involving cilchicine and apilimod is in accordance with their observed extreme toxicity in the clinic 208 [19, 20] . This case study indicates that SynToxProfiler can identify safe top hits with high selective 209 efficacy and synergy that have increased potential for clinical success, as compared to hits selected 210 based on synergy alone. The primary motivation for the use of synergistic drug combinations in the clinic is to achieve higher 222 efficacy (by means of drug interaction) with reduced toxicity (by decreasing the drug doses). 223 Therefore, the HTS screening aims to discover drug pairs that are more effective than the individual 224 single drugs, and, at the same time, show less toxicity for the patients. Hence, the assessment of 225 synergistic efficacy along with toxicity is critical for the selection of candidate drug pairs for further 226 study, as there exists a fundamental trade-off between clinical efficacy and tolerable toxicity. 227
228
To the best of our knowledge, there are currently no methods to provide the global view in terms of 229 synergy, efficacy and toxicity of drug pairs in an HTS setting. In this respect, SynToxProfiler offers an 230 important advancement into the current practice for drug combination selection, as it provides an easy-231 to-use platform for in-vitro or ex-vivo assessment of the three critical aspects of drug combinations 232 that are necessary for success in the clinics. Furthermore, SynToxProfiler facilitates the identification 233 of therapeutic window range at which the drugs show highest synergy, high efficacy and lowest 234 toxicity by visualization of the dose-response surfaces. Since, SynToxProfiler uses the normalized 235 volume-based scoring for synergy, efficacy and toxicity levels (see methods and supplementary file), 236
the SynToxProfiler framework can be easily utilized to prioritize synergistic drug combinations with 237 high selective efficacy for multi-component (3 or more drugs) drug combination screening. Since 238 limited number of tools and methodology are available to analyze and interpret either synergy, efficacy 239 or toxicity of multi-component drug combinations, SynToxProfiler will be valuable resource for 240 screening of such combinations. 241
242
In this work, we showed how SynToxProviler prioritized cytarabine-daunorubicin as the top drug pair 243 out of 20 anticancer combinations for T-PLL case study (Table 1) , and clomifene-sertraline for anti-244 viral case study (Additional file 2). The identification of clinically established drug pairs as top hit 245 suggests that ranking based on all the three parameters can help to identify combinations that have 246 more chance to success in the clinic. These effective and safe combinations would have been otherwise 247 missed if combinations were selected merely based on their synergy scores. 248
249
In conclusion, we have developed SynToxProfiler, an interactive tool for top hit prioritization that 250 ranks drug pairs based on their combined synergy, efficacy and toxicity profile, and which can be 251 applied to any HTS drug combination screening project. We showed how this tool enable identification 252 of clinically established drug pairs as top hits and many more drug pairs with a translational potential. 253
We foresee SynToxProfiler will allow for more unbiased and systematic means to evaluate the pre-254 clinical potency of drug combinations toward safe and effective therapeutic applications. 255 256
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